Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis

Abstract Background Primary hyperparathyroidism (PHPT) is characterized by persistent hypercalcemia caused by parathyroid adenomas. Preoperative localization of hyperfunctional parathyroids is crucial to optimize surgical outcomes. Current standard practice combines cervical ultrasound (CU), [99mTc]...

Full description

Saved in:
Bibliographic Details
Main Authors: Adel Mamou, Sihame Chkair, Olivier Gilly, Laurent Maimoun, Yassine Mamou, Sean C. Sheppard, Pierre Olivier Kotzki, Benjamin Lallemant, Vincent Boudousq
Format: Article
Language:English
Published: Springer 2025-04-01
Series:EJNMMI Reports
Subjects:
Online Access:https://doi.org/10.1186/s41824-025-00244-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850153910499540992
author Adel Mamou
Sihame Chkair
Olivier Gilly
Laurent Maimoun
Yassine Mamou
Sean C. Sheppard
Pierre Olivier Kotzki
Benjamin Lallemant
Vincent Boudousq
author_facet Adel Mamou
Sihame Chkair
Olivier Gilly
Laurent Maimoun
Yassine Mamou
Sean C. Sheppard
Pierre Olivier Kotzki
Benjamin Lallemant
Vincent Boudousq
author_sort Adel Mamou
collection DOAJ
description Abstract Background Primary hyperparathyroidism (PHPT) is characterized by persistent hypercalcemia caused by parathyroid adenomas. Preoperative localization of hyperfunctional parathyroids is crucial to optimize surgical outcomes. Current standard practice combines cervical ultrasound (CU), [99mTc]Tc-sestaMIBI SPECT scintigraphy (MIBI), and [18F]Fluorocholine PET/CT (PET) centered on the cervico-thoracic region. This study evaluates the cost-effectiveness of PET as a stand-alone first-line imaging strategy compared to CU + MIBI + PET and CU + PET strategies in the French healthcare system. Methods A Markov model estimated costs and quality-adjusted life years (QALYs) for each imaging strategy. Imaging performance parameters were derived from a cohort of 145 PHPT patients who underwent surgery after all three imaging exams. Costs were calculated from the perspective of the French healthcare system, and utilities were sourced from the literature and validated by experts. Probabilistic and deterministic sensitivity analyses assessed robustness, while a Budget Impact Analysis (BIA) evaluated financial implications of national adoption over three years (2025–2027). Results The average costs per patient were €5175 for CU + MIBI + PET, €5406 for CU + PET, and €5320 for PET alone, with corresponding QALYs of 13.80, 13.81, and 13.82. PET alone had an incremental cost-effectiveness ratio (ICER) of €12,650/QALY and an incremental net monetary benefit (iNMB) of 855€ compared to CU + MIBI + PET but offered only marginal QALY gains (+ 0.02), which were not substantially different. Sensitivity analyses revealed PET alone becomes dominant if [99mTc]Tc-MIBI SPECT sensitivity falls below 75.5% or PET costs drop below €632. Conclusion [18F]Fluorocholine PET/CT stand-alone could be a cost-effective option and considered as a first line imaging strategy. Imaging strategies should be adapted to local healthcare contexts, reimbursement models, and diagnostic performance to optimize cost-effectiveness and patient care.
format Article
id doaj-art-2dabfc5a426b405fbb2600a0940e54dc
institution OA Journals
issn 3005-074X
language English
publishDate 2025-04-01
publisher Springer
record_format Article
series EJNMMI Reports
spelling doaj-art-2dabfc5a426b405fbb2600a0940e54dc2025-08-20T02:25:36ZengSpringerEJNMMI Reports3005-074X2025-04-019111810.1186/s41824-025-00244-wEconomic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysisAdel Mamou0Sihame Chkair1Olivier Gilly2Laurent Maimoun3Yassine Mamou4Sean C. Sheppard5Pierre Olivier Kotzki6Benjamin Lallemant7Vincent Boudousq8Department of Nuclear Medicine, CHU Nîmes, Univ MontpellierDepartment of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ MontpellierDepartment of Metabolic and Endocrine Disease, CHU Nîmes, Univ MontpellierDepartment of Nuclear Medicine, CHU Nîmes, Univ MontpellierDepartment of Nuclear Medicine, CHU Nîmes, Univ MontpellierDepartment of Otolaryngology, CHU Nîmes, Univ MontpellierDepartment of Nuclear Medicine, CHU Nîmes, Univ MontpellierDepartment of Otolaryngology, CHU Nîmes, Univ MontpellierDepartment of Nuclear Medicine, CHU Nîmes, Univ MontpellierAbstract Background Primary hyperparathyroidism (PHPT) is characterized by persistent hypercalcemia caused by parathyroid adenomas. Preoperative localization of hyperfunctional parathyroids is crucial to optimize surgical outcomes. Current standard practice combines cervical ultrasound (CU), [99mTc]Tc-sestaMIBI SPECT scintigraphy (MIBI), and [18F]Fluorocholine PET/CT (PET) centered on the cervico-thoracic region. This study evaluates the cost-effectiveness of PET as a stand-alone first-line imaging strategy compared to CU + MIBI + PET and CU + PET strategies in the French healthcare system. Methods A Markov model estimated costs and quality-adjusted life years (QALYs) for each imaging strategy. Imaging performance parameters were derived from a cohort of 145 PHPT patients who underwent surgery after all three imaging exams. Costs were calculated from the perspective of the French healthcare system, and utilities were sourced from the literature and validated by experts. Probabilistic and deterministic sensitivity analyses assessed robustness, while a Budget Impact Analysis (BIA) evaluated financial implications of national adoption over three years (2025–2027). Results The average costs per patient were €5175 for CU + MIBI + PET, €5406 for CU + PET, and €5320 for PET alone, with corresponding QALYs of 13.80, 13.81, and 13.82. PET alone had an incremental cost-effectiveness ratio (ICER) of €12,650/QALY and an incremental net monetary benefit (iNMB) of 855€ compared to CU + MIBI + PET but offered only marginal QALY gains (+ 0.02), which were not substantially different. Sensitivity analyses revealed PET alone becomes dominant if [99mTc]Tc-MIBI SPECT sensitivity falls below 75.5% or PET costs drop below €632. Conclusion [18F]Fluorocholine PET/CT stand-alone could be a cost-effective option and considered as a first line imaging strategy. Imaging strategies should be adapted to local healthcare contexts, reimbursement models, and diagnostic performance to optimize cost-effectiveness and patient care.https://doi.org/10.1186/s41824-025-00244-w[18F]fluorocholine PET/CTPrimary hyperparathyroidismParathyroid[99mTc]Tc-MIBI scintigraphyCost evaluationMarkov model
spellingShingle Adel Mamou
Sihame Chkair
Olivier Gilly
Laurent Maimoun
Yassine Mamou
Sean C. Sheppard
Pierre Olivier Kotzki
Benjamin Lallemant
Vincent Boudousq
Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
EJNMMI Reports
[18F]fluorocholine PET/CT
Primary hyperparathyroidism
Parathyroid
[99mTc]Tc-MIBI scintigraphy
Cost evaluation
Markov model
title Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
title_full Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
title_fullStr Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
title_full_unstemmed Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
title_short Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis
title_sort economic evaluation of 18f fluorocholine pet ct in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism a cost effectiveness analysis
topic [18F]fluorocholine PET/CT
Primary hyperparathyroidism
Parathyroid
[99mTc]Tc-MIBI scintigraphy
Cost evaluation
Markov model
url https://doi.org/10.1186/s41824-025-00244-w
work_keys_str_mv AT adelmamou economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT sihamechkair economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT oliviergilly economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT laurentmaimoun economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT yassinemamou economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT seancsheppard economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT pierreolivierkotzki economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT benjaminlallemant economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis
AT vincentboudousq economicevaluationof18ffluorocholinepetctinpreoperativeassessmentofhyperfunctionalparathyroidsinprimaryhyperparathyroidismacosteffectivenessanalysis